Immunization of rhesus macaques with a polyvalent DNA prime/protein boost human immunodeficiency virus type 1 vaccine elicits protective antibody response against simian human immunodeficiency virus of R5 phenotype

Virology

Volumn 348, Issue 2, 2006, Pages 341-353

  Pal, Ranajit ^a   Wang, Shixia ^b   Kalyanaraman, V S ^a   Nair, B C ^a   Whitney, Stephen ^a   Keen, Timothy ^a   Hocker, Lindsey ^a   Hudacik, Lauren ^a   Rose, Nicolas ^a   Mboudjeka, Innocent ^b   Shen, Siyuan ^b   Wu Chou, Te Hui ^b   Montefiori, David ^c   Mascola, John ^d   Markham, Phillip ^a   Lu, Shan ^b  

^a ADVANCED BIOSCIENCE LABORATORIES INC   (United States)

^b UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^c DUKE UNIVERSITY   (United States)

^d Vaccine Research Center   (United States)

Author keywords

Hiv 1 vaccine; Mucosal transmission; Neutralizing antibody; Nonhuman primates; R5 SHIV

Indexed keywords

DNA VACCINE; GAG PROTEIN; GLYCOPROTEIN GP 120; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; SUBUNIT VACCINE; VIRUS ANTIBODY;

ANIMAL; ARTICLE; BIOSYNTHESIS; CELLULAR IMMUNITY; CLASSIFICATION; GENETICS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNIZATION; IMMUNOLOGY; MACACA; MONKEY DISEASE; PATHOGENICITY; PHENOTYPE; SERODIAGNOSIS; SIMIAN IMMUNODEFICIENCY VIRUS;

AIDS VACCINES; ANIMALS; ANTIBODIES, VIRAL; GENE PRODUCTS, GAG; HIV ENVELOPE PROTEIN GP120; HIV-1; HUMANS; IMMUNITY, CELLULAR; IMMUNIZATION SCHEDULE; IMMUNIZATION, SECONDARY; MACACA MULATTA; NEUTRALIZATION TESTS; PHENOTYPE; SIMIAN ACQUIRED IMMUNODEFICIENCY SYNDROME; SIMIAN IMMUNODEFICIENCY VIRUS; VACCINES, DNA; VACCINES, SUBUNIT;

EID: 33745496632     PISSN: 00426822     EISSN: 10960341     Source Type: Journal    
DOI: 10.1016/j.virol.2005.12.029     Document Type: Article

References (55)

1. Adachi, A., Gendelman, H.E., Koenig, S., Folks, T., Willey, R., Rabson, A., Martin, M.A., 1986. Production of acquired immunodeficiency syndromeassociated retrovirus in human and nonhuman cells transfected with an infectious molecular clone. J. Virol. 59 (2), 284-291.
2. Alvarez, D., Harder, G., Fattouh, R., Sun, J., Goncharova, S., Stampfli, M.R., Coyle, A.J., Bramson, J.L., Jordana, M., 2005. Cutaneous antigen priming via gene gun leads to skin-selective Th2 immune-inflammatory responses. J. Immunol. 174 (3), 1664-1674.
3. Amara, R.R., Villinger, F., Altman, J.D., Lydy, S.L., O'Neil, S.P., Staprans, S.I., Montefiori, D.C., Xu, Y., Herndon, J.G.,Wyatt, L.S., Candido, M.A., Kozyr, N.L., Earl, P.L., Smith, J.M., Ma, H.L., Grimm, B.D., Hulsey, M.L., Miller, J., McClure, H.M., McNicholl, J.M., Moss, B., Robinson, H.L., 2001. Control of a mucosal challenge and prevention of AIDS by a multiprotein DNA/MVA vaccine. Science 292 (5514), 69-74.
4. Amara, R.R., Smith, J.M., Staprans, S.I., Montefiori, D.C., Villinger, F., Altman, J.D., O'Neil, S.P., Kozyr, N.L., Xu, Y., Wyatt, L.S., Earl, P.L., Herndon, J.G., McNicholl, J.M., McClure, H.M., Moss, B., Robinson, H.L., 2002. Critical role for Env as well as Gag-Pol in control of a simian-human immunodeficiency virus 89.6P challenge by a DNA prime/recombinant modified vaccinia virus Ankara vaccine. J. Virol. 76 (12), 6138-6146.
5. Barnett, S.W., Rajasekar, S., Legg, H., Doe, B., Fuller, D.H., Haynes, J.R., Walker, C.M., Steimer, K.S., 1997. Vaccination with HIV-1 gp120 DNA induces immune responses that are boosted by a recombinant gp120 protein subunit. Vaccine 15 (8), 869-873.
6. Barouch, D.H., Santra, S., Schmitz, J.E., Kuroda, M.J., Fu, T.M., Wagner, W., Bilska, M., Craiu, A., Zheng, X.X., Krivulka, G.R., Beaudry, K., Lifton, M.A., Nickerson, C.E., Trigona, W.L., Punt, K., Freed, D.C., Guan, L., Dubey, S., Casimiro, D., Simon, A., Davies, M.E., Chastain, M., Strom, T.B., Gelman, R.S., Montefiori, D.C., Lewis, M.G., Emini, E.A., Shiver, J.W., Letvin, N.L., 2000. Control of viremia and prevention of clinical AIDS in rhesus monkeys by cytokine-augmented DNA vaccination. Science 290 (5491), 486-492.
7. Buckner, C., Gines, L.G., Saunders, C.J., Vojtech, L., Srivastava, I., Gettie, A., Bohm, R., Blanchard, J., Barnett, S.W., Safrit, J.T., Stamatatos, L., 2004. Priming B cell-mediated anti-HIV envelope responses by vaccination allows for the long-term control of infection in macaques exposed to a R5-tropic SHIV. Virology 320 (1), 167-180.
8. Calarota, S.A., Weiner, D.B., 2004. Enhancement of human immunodeficiency virus type 1-DNA vaccine potency through incorporation of T-helper 1 molecular adjuvants. Immunol. Rev. 199, 84-99.
9. Cherpelis, S., Jin, X., Gettie, A., Ho, D.D., Barnett, S.W., Shrivastava, I., Stamatatos, L., 2001a. DNA-immunization with a V2 deleted HIV-1 envelope elicits protective antibodies in macaques. Immunol. Lett. 79 (1-2), 47-55.
10. Cherpelis, S., Shrivastava, I., Gettie, A., Jin, X., Ho, D.D., Barnett, S.W., Stamatatos, L., 2001b. DNAvaccination with the human immunodeficiency virus type 1 SF162DeltaV2 envelope elicits immune responses that offer partial protection from simian/human immunodeficiency virus infection to CD8 (+) T-cell-depleted rhesus macaques. J. Virol. 75 (3), 1547-1550.
11. Cho, M.W., Kim, Y.B., Lee, M.K., Gupta, K.C., Ross, W., Plishka, R., Buckler-White, A., Igarashi, T., Theodore, T., Byrum, R., Kemp, C., Montefiori, D.C., Martin, M.A., 2001. Polyvalent envelope glycoprotein vaccine elicits a broader neutralizing antibody response but is unable to provide sterilizing protection against heterologous Simian/human immunodeficiency virus infection in pigtailed macaques. J. Virol. 75 (5), 2224-2234.
12. Clements-Mann, M.L.,Weinhold, K., Matthews, T.J., Graham, B.S., Gorse, G.J., Keefer, M.C., McElrath, M.J., Hsieh, R.H., Mestecky, J., Zolla-Pazner, S., Mascola, J., Schwartz, D., Siliciano, R., Corey, L., Wright, P.F., Belshe, R., Dolin, R., Jackson, S., Xu, S., Fast, P., Walker, M.C., Stablein, D., Excler, J.L., Tartaglia, J., Paoletti, E., et al., 1998. Immune responses to human immunodeficiency virus (HIV) type 1 induced by canarypox expressing HIV-1MN gp120, HIV-1SF2 recombinant gp120, or both vaccines in seronegative adults. NIAID AIDS Vaccine Evaluation Group. J. Infect. Dis. 177 (5), 1230-1246.
13. Crawford, J.M., Earl, P.L., Moss, B., Reimann, K.A., Wyand, M.S., Manson, K.H., Bilska, M., Zhou, J.T., Pauza, C.D., Parren, P.W., Burton, D.R., Sodroski, J.G., Letvin, N.L., Montefiori, D.C., 1999. Characterization of primary isolate-like variants of simian-human immunodeficiency virus. J. Virol. 73 (12), 10199-10207.
14. Doria-Rose, N.A., Ohlen, C., Polacino, P., Pierce, C.C., Hensel, M.T., Kuller, L., Mulvania, T., Anderson, D., Greenberg, P.D., Hu, S.L., Haigwood, N.L., 2003. Multigene DNA priming-boosting vaccines protect macaques from acute CD4+-T-cell depletion after simian-human immunodeficiency virus SHIV89.6P mucosal challenge. J. Virol. 77 (21), 11563-11577.
15. Earl, P.L., Sugiura, W., Montefiori, D.C., Broder, C.C., Lee, S.A., Wild, C., Lifson, J., Moss, B., 2001. Immunogenicity and protective efficacy of oligomeric human immunodeficiency virus type 1 gp140. J. Virol. 75 (2), 645-653.
16. Earl, P.L., Wyatt, L.S., Montefiori, D.C., Bilska, M., Woodward, R., Markham, P.D., Malley, J.D., Vogel, T.U., Allen, T.M.,Watkins, D.I., Miller, N., Moss, B., 2002. Comparison of vaccine strategies using recombinant env-gag-pol MVA with or without an oligomeric Env protein boost in the SHIV rhesus macaque model. Virology 294 (2), 270-281.
17. Estcourt, M.J., McMichael, A.J., Hanke, T., 2004. DNAvaccines against human immunodeficiency virus type 1. Immunol. Rev. 199, 144-155.
18. Fatkenheuer, G., Theisen, A., Rockstroh, J., Grabow, T., Wicke, C., Becker, K., Wieland, U., Pfister, H., Reiser, M., Hegener, P., Franzen, C., Schwenk, A., Salzberger, B., 1997. Virological treatment failure of protease inhibitor therapy in an unselected cohort of HIV-infected patients. AIDS 11 (14), F113-F116.
19. Feltquate, D.M., Heaney, S., Webster, R.G., Robinson, H.L., 1997. Different T helper cell types and antibody isotypes generated by saline and gene gun DNA immunization. J. Immunol. 158 (5), 2278-2284.
20. Gauduin, M.C., Parren, P.W., Weir, R., Barbas, C.F., Burton, D.R., Koup, R.A., 1997. Passive immunization with a human monoclonal antibody protects hu-PBL-SCID mice against challenge by primary isolates of HIV-1. Nat. Med. 3 (12), 1389-1393.
21. Gilbert, P.B., Peterson, M.L., Follmann, D., Hudgens, M.G., Francis, D.P., Gurwith, M., Heyward, W.L., Jobes, D.V., Popovic, V., Self, S.G., Sinangil, F., Burke, D., Berman, P.W., 2005. Correlation between immunologic responses to a recombinant glycoprotein 120 vaccine and incidence of HIV-1 infection in a phase 3 HIV-1 preventive vaccine trial. J. Infect. Dis. 191 (5), 666-677.
22. Graham, B.S., Matthews, T.J., Belshe, R.B., Clements, M.L., Dolin, R., Wright, P.F., Gorse, G.J., Schwartz, D.H., Keefer, M.C., Bolognesi, D.P., et al., 1993. Augmentation of human immunodeficiency virus type 1 neutralizing antibody by priming with gp160 recombinant vaccinia and boosting with rgp160 in vaccinia-naive adults. The NIAID AIDS Vaccine Clinical Trials Network. J. Infect. Dis. 167 (3), 533-537.
23. Harouse, J.M., Gettie, A., Tan, R.C., Blanchard, J., Cheng-Mayer, C., 1999. Distinct pathogenic sequela in rhesus macaques infected with CCR5 or CXCR4 utilizing SHIVs. Science 284 (5415), 816-819.
24. Kjerrstrom, A., Hinkula, J., Engstrom, G., Ovod, V., Krohn, K., Benthin, R., Wahren, B., 2001. Interactions of single and combined human immunodeficiency virus type 1 (HIV-1) DNA vaccines. Virology 284 (1), 46-61.
25. Kong, W.P., Huang, Y., Yang, Z.Y., Chakrabarti, B.K., Moodie, Z., Nabel, G.J., 2003. Immunogenicity of multiple gene and clade human immunodeficiency virus type 1 DNA vaccines. J. Virol. 77 (23), 12764-12772.
26. Letvin, N.L., 1998. Progress in the development of an HIV-1 vaccine. Science 280 (5371), 1875-1880.
27. Letvin, N.L., 2005. Progress toward an HIV vaccine. Annu. Rev. Med. 56, 213-223.
28. Letvin, N.L., Barouch, D.H., Montefiori, D.C., 2002. Prospects for vaccine protection against HIV-1 infection and AIDS. Annu. Rev. Immunol. 20, 73-99.
29. Letvin, N.L., Huang, Y., Chakrabarti, B.K., Xu, L., Seaman, M.S., Beaudry, K., Korioth-Schmitz, B., Yu, F., Rohne, D., Martin, K.L., Miura, A., Kong,W.P., Yang, Z.Y., Gelman, R.S., Golubeva, O.G., Montefiori, D.C., Mascola, J.R., Nabel, G.J., 2004. Heterologous envelope immunogens contribute to AIDS vaccine protection in rhesus monkeys. J. Virol. 78 (14), 7490-7497.
30. Leung, L., Srivastava, I.K., Kan, E., Legg, H., Sun, Y., Greer, C., Montefiori, D.C., zur Megede, J., Barnett, S.W., 2004. Immunogenicity of HIV-1 Env and Gag in baboons using a DNA prime/protein boost regimen. AIDS 18 (7), 991-1001.
31. Lewis, M.G., Elkins, W.R., McCutchan, F.E., Benveniste, R.E., Lai, C.Y., Montefiori, D.C., Burke, D.S., Eddy, G.A., Shafferman, A., 1993. Passively transferred antibodies directed against conserved regions of SIV envelope protect macaques from SIV infection. Vaccine 11 (13), 1347-1355.
32. Lu, S., Manning, S., Arthos, J., 1999. Antigen engineering in DNA immunization. In: Lowrie, D.B., Whalen, R. (Eds.), Methods in Molecular Medicine, DNA Vaccines: Methods and Protocols, vol. 29. Humana Press Inc, Totowa, NJ, pp. 355-374.
33. Mascola, J.R., Nabel, G.J., 2001. Vaccines for the prevention of HIV-1 disease. Curr. Opin. Immunol. 13 (4), 489-495.
34. Mascola, J.R., Lewis, M.G., Stiegler, G., Harris, D., VanCott, T.C., Hayes, D., Louder, M.K., Brown, C.R., Sapan, C.V., Frankel, S.S., Lu, Y., Robb, M.L., Katinger, H., Birx, D.L., 1999. Protection of macaques against pathogenic simian/human immunodeficiency virus 89.6PD by passive transfer of neutralizing antibodies. J. Virol. 73 (5), 4009-4018.
35. Mascola, J.R., Stiegler, G., VanCott, T.C., Katinger, H., Carpenter, C.B., Hanson, C.E., Beary, H., Hayes, D., Frankel, S.S., Birx, D.L., Lewis, M.G., 2000. Protection of macaques against vaginal transmission of a pathogenic HIV-1/SIV chimeric virus by passive infusion of neutralizing antibodies. Nat. Med. 6 (2), 207-210.
36. Mascola, J.R., Louder, M.K.,Winter, C., Prabhakara, R., De Rosa, S.C., Douek, D.C., Hill, B.J., Gabuzda, D., Roederer, M., 2002. Human immunodeficiency virus type 1 neutralization measured by flow cytometric quantitation of single-round infection of primary human T cells. J. Virol. 76 (10), 4810-4821.
37. Mocroft, A., Ledergerber, B., Katlama, C., Kirk, O., Reiss, P., d'Arminio Monforte, A., Knysz, B., Dietrich, M., Phillips, A.N., Lundgren, J.D., 2003a. Decline in the AIDS and death rates in the EuroSIDA study: an observational study. Lancet 362 (9377), 22-29.
38. Mocroft, A., Ruiz, L., Reiss, P., Ledergerber, B., Katlama, C., Lazzarin, A., Goebel, F.D., Phillips, A.N., Clotet, B., Lundgren, J.D., 2003b. Virological rebound after suppression on highly active antiretroviral therapy. AIDS 17 (12), 1741-1751.
39. Montefiori, D.C., 2004. Evaluating neutralizing antibodies against HIV, SIVand SHIV in luciferase reporter gene assays. In: Coligan, J.E., Kruisbeek, A.M., Margulies, D.H., Shevach, E.M., Strober, W., Coico, R. (Eds.), Current Protocols in Immunology. John Wiley and Sons, NY, pp. 12.11.1-12.11.15.
40. Nabel, G.J., 2001. Challenges and opportunities for development of an AIDS vaccine. Nature 410 (6831), 1002-1007.
41. Nabel, G., Makgoba, W., Esparza, J., 2002. HIV-1 diversity and vaccine development. Science 296 (5577), 2335.
42. Pal, R., Venzon, D., Letvin, N.L., Santra, S., Montefiori, D.C., Miller, N.R., Tryniszewska, E., Lewis, M.G., VanCott, T.C., Hirsch, V., Woodward, R., Gibson, A., Grace, M., Dobratz, E., Markham, P.D., Hel, Z., Nacsa, J., Klein, M., Tartaglia, J., Franchini, G., 2002. ALVAC-SIV-gag-pol-env-based vaccination and macaque major histocompatibility complex class I (A01) delay simian immunodeficiency virus SIVmac-induced immunodeficiency. J. Virol. 76 (1), 292-302.
43. Pal, R., Taylor, B., Foulke, J.S., Woodward, R., Merges, M., Praschunus, R., Gibson, A., Reitz, M., 2003. Characterization of a simian human immunodeficiency virus encoding the envelope gene from the CCR5-tropic HIV-1 Ba-L. J. Acquired Immune Defic. Syndr. 33 (3), 300-307.
44. Pantaleo, G., Fauci, A.S., 1996. Immunopathogenesis of HIV infection. Annu. Rev. Microbiol. 50, 825-854.
45. Richmond, J.F., Mustafa, F., Lu, S., Santoro, J.C., Weng, J., O'Connell, M., Fenyo, E.M., Hurwitz, J.L., Montefiori, D.C., Robinson, H.L., 1997. Screening of HIV-1 Env glycoproteins for the ability to raise neutralizing antibody using DNA immunization and recombinant vaccinia virus boosting. Virology 230 (2), 265-274.
46. Robinson, H.L., 1999. DNA vaccines: basic mechanism and immune responses (Review). Int. J. Mol. Med. 4 (5), 549-555.
47. Romano, J.W., Shurtliff, R.N., Dobratz, E., Gibson, A., Hickman, K., Markham, P.D., Pal, R., 2000. Quantitative evaluation of simian immunodeficiency virus infection using NASBA technology. J. Virol. Methods 86 (1), 61-70.
48. Seaman, M.S., Xu, L., Beaudry, K., Martin, K.L., Beddall, M.H., Miura, A., Sambor, A., Chakrabarti, B.K., Huang, Y., Bailer, R., Koup, R.A., Mascola, J.R., Nabel, G.J., Letvin, N.L., 2005. Multiclade human immunodeficiency virus type 1 envelope immunogens elicit broad cellular and humoral immunity in rhesus monkeys. J. Virol. 79 (5), 2956-2963.
49. Sedegah, M., Charoenvit, Y., Minh, L., Belmonte, M., Majam, V.F., Abot, S., Ganeshan, H., Kumar, S., Bacon, D.J., Stowers, A., Narum, D.L., Carucci, D.J., Rogers, W.O., 2004. Reduced immunogenicity of DNA vaccine plasmids in mixtures. Gene Ther. 11 (5), 448-456.
50. Shelburne, S.A., Visnegarwala, F., Darcourt, J., Graviss, E.A., Giordano, T.P., White Jr., A.C., Hamill, R.J., 2005. Incidence and risk factors for immune reconstitution inflammatory syndrome during highly active antiretroviral therapy. AIDS 19 (4), 399-406.
51. Shibata, R., Igarashi, T., Haigwood, N., Buckler-White, A., Ogert, R., Ross, W., Willey, R., Cho, M.W., Martin, M.A., 1999. Neutralizing antibody directed against the HIV-1 envelope glycoprotein can completely block HIV-1/SIV chimeric virus infections of macaque monkeys. Nat. Med. 5 (2), 204-210.
52. Shiver, J.W., Fu, T.M., Chen, L., Casimiro, D.R., Davies, M.E., Evans, R.K., Zhang, Z.Q., Simon, A.J., Trigona, W.L., Dubey, S.A., Huang, L., Harris, V.A., Long, R.S., Liang, X., Handt, L., Schleif, W.A., Zhu, L., Freed, D.C., Persaud, N.V., Guan, L., Punt, K.S., Tang, A., Chen, M., Wilson, K.A., Collins, K.B., Heidecker, G.J., Fernandez, V.R., Perry, H.C., Joyce, J.G., Grimm, K.M., Cook, J.C., Keller, P.M., Kresock, D.S., Mach, H., Troutman, R.D., Isopi, L.A., Williams, D.M., Xu, Z., Bohannon, K.E., Volkin, D.B., Montefiori, D.C., Miura, A., Krivulka, G.R., Lifton, M.A., Kuroda, M.J., Schmitz, J.E., Letvin, N.L., Caulfield, M.J., Bett, A.J., Youil, R., Kaslow, D.C., Emini, E.A., 2002. Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency-virus immunity. Nature 415 (6869), 331-335.
53. Soudeyns, H., Pantaleo, G., 1999. The moving target: mechanisms of HIV persistence during primary infection. Immunol. Today 20 (10), 446-450.
54. Weiss, R., Scheiblhofer, S., Freund, J., Ferreira, F., Livey, I., Thalhamer, J., 2002. Gene gun bombardment with gold particles displays a particular Th2-promoting signal that over-rules the Th1-inducing effect of immunostimulatory CpG motifs in DNA vaccines. Vaccine 20 (25-26), 3148-3154.
55. Wit, F.W., van Leeuwen, R., Weverling, G.J., Jurriaans, S., Nauta, K., Steingrover, R., Schuijtemaker, J., Eyssen, X., Fortuin, D., Weeda, M., de Wolf, F., Reiss, P., Danner, S.A., Lange, J.M., 1999. Outcome and predictors of failure of highly active antiretroviral therapy: one-year follow-up of a cohort of human immunodeficiency virus type 1-infected persons. J. Infect. Dis. 179 (4), 790-798.